Literature DB >> 23551407

Expert-based drug lists to measure anticholinergic burden: similar names, different results.

Unax Lertxundi1, Saioa Domingo-Echaburu, Rafael Hernandez, Javier Peral, Juan Medrano.   

Abstract

BACKGROUND: Scoring scales such as the Anticholinergic Drug Scale (ADS), the Anticholinergic Risk Scale (ARS), and the Anticholinergic Cognitive Burden Scale (ACB) provide an estimation of total anticholinergic burden. Not all the lists include the same drugs, and the points given for certain drugs differ among them. Whether these discrepancies present important differences in the estimation of anticholinergic burden for an individual patient is unknown. Therefore, the aim of this study is to assess agreement among the three scales.
METHOD: Anticholinergic burden was measured with the three scales in 83 patients aged ≥65 years in a medium- and long-stay psychiatric hospital. Subsequently, patients were categorized into three risk categories: low risk (0 points), medium risk (1-2 points) or high risk (3 or more points). The chance-corrected measures of agreement for the different scores were determined with the k-statistic (kappa).
RESULTS: Values for kappa were: 0.19 for Anticholinergic Risk Scale-Anticholinergic Drug Scale, 0.21 for ACB-Anticholinergic Drug Scale and 0.25 for Anticholinergic Risk Scale-ACB. The mean anticholinergic burden measured with ACB was 3.28.
CONCLUSIONS: There is poor agreement among the three scales. These lists cannot be directly applied to different settings in which drug availability differs substantially, and they require periodic updates. Anticholinergic burden in our setting (psychogeriatric inpatients) was particularly high.
© 2013 The Authors. Psychogeriatrics © 2013 Japanese Psychogeriatric Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551407     DOI: 10.1111/j.1479-8301.2012.00418.x

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  32 in total

Review 1.  The Association Between Anticholinergic Medication Burden and Health Related Outcomes in the 'Oldest Old': A Systematic Review of the Literature.

Authors:  Karen Cardwell; Carmel M Hughes; Cristín Ryan
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

2.  Comments on Duran et al.'s systematic review of anticholinergic risk scales (EJCP 2DOI 10.1007/s00228-013-1499-3).

Authors:  Unax Lertxundi; Saioa Domingo-Echaburu; Borja Ruiz-Osante; Rafael Hernandez Palacios; Javier Peral Aguirregoitia; Juan Medrano Albeniz
Journal:  Eur J Clin Pharmacol       Date:  2013-06-06       Impact factor: 2.953

3.  Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French PharmacoVigilance Database.

Authors:  François Montastruc; Sarah Rouanet; Virginie Gardette; Vanessa Rousseau; Haleh Bagheri; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2015-05-21       Impact factor: 2.953

4.  Concordance Between Anticholinergic Burden Scales.

Authors:  Jennifer G Naples; Zachary A Marcum; Subashan Perera; Shelly L Gray; Anne B Newman; Eleanor M Simonsick; Kristine Yaffe; Ronald I Shorr; Joseph T Hanlon
Journal:  J Am Geriatr Soc       Date:  2015-10       Impact factor: 5.562

5.  Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures.

Authors:  Lisa G Pont; Johannes T H Nielen; Andrew J McLachlan; Danijela Gnjidic; Lewis Chan; Robert G Cumming; Katja Taxis
Journal:  Br J Clin Pharmacol       Date:  2015-07-06       Impact factor: 4.335

6.  Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients.

Authors:  Sermin Toto; Gudrun Hefner; Martina Hahn; Christoph Hiemke; Sibylle C Roll; Jan Wolff; Ansgar Klimke
Journal:  J Neural Transm (Vienna)       Date:  2021-01-13       Impact factor: 3.575

Review 7.  Different methods, different results--how do available methods link a patient's anticholinergic load with adverse outcomes?

Authors:  Tanja Mayer; Walter E Haefeli; Hanna M Seidling
Journal:  Eur J Clin Pharmacol       Date:  2015-09-08       Impact factor: 2.953

Review 8.  Psychopharmacological Treatment in Older People: Avoiding Drug Interactions and Polypharmacy.

Authors:  Torsten Kratz; Albert Diefenbacher
Journal:  Dtsch Arztebl Int       Date:  2019-07-22       Impact factor: 5.594

9.  DEL-FINE: a new tool for assessing the delirogenic properties of drugs of relevance for European pharmacotherapy.

Authors:  Birgit Böhmdorfer; Sonja Rohleder; Martin Wawruch; T J M van der Cammen; Thomas Frühwald; Christian Jagsch; Susanne Melitta Maria Janowitz; Marietta Nagano; Mirko Petrovic; Ulrike Sommeregger; Bernhard Iglseder
Journal:  Z Gerontol Geriatr       Date:  2015-08-19       Impact factor: 1.281

10.  Anticholinergic burden in Parkinson's disease inpatients.

Authors:  Unax Lertxundi; Arantxazu Isla; Maria Angeles Solinis; Saioa Domingo-Echaburu; Rafael Hernandez; Javier Peral-Aguirregoitia; Juan Medrano
Journal:  Eur J Clin Pharmacol       Date:  2015-08-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.